Enquiry Now
Loading...
| A03206 | Pages: NA | Aug 2021 | 4251 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Macular Edema Market
Request Now !Macular edema is a slowly progressing disease where accumulation of fluid takes place in a specialized part of the retina called the macula. Owing to the fluid retention in the retinal layer, the person may suffer from blurred or wavy central vision and/or change in appearance of colors. Most of macular edema cases are caused due to diabetes, wherein the blood vessels in the retina are usually damaged due to leakage of fluids, such as small amounts of blood. Other reasons that can lead to macular edema are side effects of certain medications, retinal vein occlusion, and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.
Increase in the prevalence and incidence of diabetes has increased the risk of diabetic macular edema, making it the major driver of the market. Furthermore, increased use of off-label drugs, such as Avastin (bevacizumab) by Roche, and the emergence of new drugs in the market further boost the market growth. Moreover, recently two drugs Ozurdex manufactured by Allergan and Lucentis developed by Roche and Novartis, which are used for the treatment of macular edema, received regulatory approvals, thus boosting the market growth. Furthermore, rise in funding for the R&D activities to tackle the burden of these chronic diseases by medical organizations and pharmaceuticals companies boosts the market.
The global macular edema market is segmented based on type, end user, and region. Based on type, it is bifurcated into cystoid macular edema and diabetic macular edema. Based on end user, it is divided into hospitals, ophthalmic clinics, research institutes, and contract research organizations. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major players, such as Acucela Inc., BCN Peptides, Aerie Pharmaceuticals, Inc., Aerpio Therapeutics, Inc., Amakem NV, Biomar Microbial Technologies, Antisense Therapeutics Limited, Charlesson LLC., Araim Pharmaceuticals, Inc., and Coherus BioSciences, are also provided in this report.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 MACULAR EDEMA MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CYSTOID MACULAR EDEMA
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. DIABETIC MACULAR EDEMA
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
CHAPTER 5 MACULAR EDEMA MARKET, BY END USERS
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HOSPITALS
5.2.1. Market size and forecast
5.3. OPHTHALMIC CLINICS
5.3.1. Market size and forecast
5.4. RESEARCH INSTITUTES
5.4.1. Market size and forecast
5.5. CONTRACT RESEARCH ORGANIZATIONS
5.5.1. Market size and forecast
CHAPTER 6 MACULAR EDEMA MARKET, BY GEOGRAPHY
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Macular Edema Market By Type
6.2.5. North America Macular Edema Market by End Users
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Macular Edema Market By Type
6.3.5. Europe Macular Edema Market by End Users
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Macular Edema Market By Type
6.4.5. Asia-Pacific Macular Edema Market by End Users
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast
6.5.4. LAMEA Macular Edema Market By Type
6.5.5. LAMEA Macular Edema Market by End Users
CHAPTER 7 COMPANY PROFILES
7.1. ACUCELA INC.
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. BCN PEPTIDES
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. AERIE PHARMACEUTICALS, INC.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. AERPIO THERAPEUTICS, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. AMAKEM NV
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. BIOMAR MICROBIAL TECHNOLOGIES
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. ANTISENSE THERAPEUTICS LIMITED
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. CHARLESSON LLC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. ARAIM PHARMACEUTICALS, INC.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. COHERUS BIOSCIENCES
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
